On March 28, 2023 Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, reported that the company will be participating in Cantor Fitzgerald’s The Future of Oncology Virtual Symposium being held April 3-5, 2023, in a virtual format (Press release, Aptose Biosciences, MAR 28, 2023, View Source [SID1234629415]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Cantor Healthcare Research team will be hosting a series of insightful fireside chats, panel presentations, and 1×1 meetings during the symposium. Aptose’s Chief Medical Officer, Rafael Bejar, M.D., Ph.D., will participate in a panel, "Targeted Therapies in AML."

Cantor’s The Future of Oncology Virtual Symposium

Panel Title: Targeted Therapies in AML
Date: Wednesday, April 5, 2023
Time: 12:00 – 12:45 PM Eastern Time
Aptose Speaker: Rafael Bejar, M.D., Ph.D., Senior Vice President and Chief Medical Officer